# Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Source: https://onco.cc/trials/nct06229340/  
OnCo record `nct06229340` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by N.N. Petrov National Medical Research Center of Oncology, now recruiting.

## Summary

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations is a phase 2, interventional study registered as NCT06229340 by N.N. Petrov National Medical Research Center of Oncology, with a registry enrolment figure of 20 participants, started 2023-10-03 and due to reach its primary completion in 2026-10-01. Interventions recorded: Leflunomide; The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab. Conditions listed: RAS Mutation; Ras (Kras or Nras) Gene Mutation; Colorectal Cancer Recurrent; Pancreas Cancer; Lung Cancer; Melanoma; Refractory Cancer. Primary outcome: Objective response rate. Sites: Russia. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: NТО-RAS
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06229340
- Phase: 2
- Setting: New Therapeutic Approaches for Tumors With RAS Gene Mutations
- Sponsor: N.N. Petrov National Medical Research Center of Oncology
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06229340: https://clinicaltrials.gov/study/NCT06229340

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06229340.json